Brian Gelbman
Pulmonary Disease · New York, NYNPI 1578501185
Payments from drug & device makers
Across 803 payments — averaging $28.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- GSK$3K
- AstraZeneca$3K
- Boehringer Ingelheim$2K
- Sanofi$1K
- Insmed, Inc.$1K
- plus $9K from 37 others
What the payments were for
- Travel & lodging$6773%
- Food & beverage$18,76181%
- Education$3,81716%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ION$3,000
- Da Vinci Surgical System$1,139
- VAPOTHERM$194
- Simulus$193
- Monarch Platform$169
- MONARCH$160
- ILLUMISITE$111
How this compares
$23,256 in reported general payments places this provider in the 85th percentile of 1,115 pulmonary disease providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 31 | $422,962 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 241 | $177,628 |
| Breo ElliptaFluticasone/Vilanterol | 216 | $100,096 |
| Dupixent PenDupilumab | 15 | $63,644 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 55 | $29,107 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 39 | $24,776 |
| Pirfenidone | 13 | $24,325 |
| EliquisApixaban | 32 | $20,854 |
| XareltoRivaroxaban | 13 | $19,535 |
| Spiriva RespimatTiotropium Bromide | 20 | $16,444 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 25 | $15,206 |
| OzempicSemaglutide | 12 | $13,154 |
| SymbicortBudesonide/Formoterol Fumarate | 39 | $12,375 |
| Arnuity ElliptaFluticasone Furoate | 27 | $10,820 |
| Sildenafil Citrate | 14 | $9,271 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $1,898 | $454,61176 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $3,341 | $317,651539 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,129 | $37,15178 claims |
| PfizerEliquis | $323 | $20,85432 claims |
| Johnson & JohnsonXarelto | $447 | $19,53513 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $89 | $6,60819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in New York
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Doreen Addrizzo-HarrisNew York$1.9M
- Emily DimangoNew York$1.4M
- da ZhangNew York$1.3M
- Claire KeatingNew York$1.2M
- Charles PowellNew York$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.